{"name":"Cellectis","slug":"cellectis","ticker":"CLLS","exchange":"NASDAQ","domain":"cellectis.com","description":"Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.","hq":"Paris, France","founded":2007,"employees":"224","ceo":"Andre Choulika","sector":"Cell & Gene Therapy / Immuno-Oncology","stockPrice":3.54,"stockChange":0.18,"stockChangePercent":5.36,"marketCap":"$356M","metrics":{"revenue":79593000,"revenueGrowth":-19.5,"grossMargin":100,"rdSpend":0,"netIncome":-67593000,"cash":206380992,"dividendYield":0,"peRatio":-5.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"UCART19 patent cliff ($0.0B at risk)","drug":"UCART19","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"UCART123v1.2","genericName":"UCART123v1.2","slug":"ucart123v1-2","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"UCART123v1.2","genericName":"UCART123v1.2","slug":"ucart123v1-2","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Cellectis Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Cellectis reported its financial results for the fourth quarter and full year 2022, with revenue of $13.4 million and a net loss of $44.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-12-06","type":"deal","headline":"Cellectis Announces Collaboration with Servier to Develop Allogenic CAR-T Therapies","summary":"Cellectis announced a collaboration with Servier to develop allogenic CAR-T therapies for the treatment of blood cancers.","drugName":"","sentiment":"positive"},{"date":"2022-09-01","type":"trial","headline":"Cellectis Announces Positive Interim Results from Phase 1 Clinical Trial of UCART19","summary":"Cellectis announced positive interim results from a Phase 1 clinical trial of UCART19, its lead allogenic CAR-T therapy candidate.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-20","type":"earnings","source":"SEC EDGAR","summary":"20-F filed with SEC: 20-F","headline":"Annual Report (20-F) Filed","sentiment":"neutral"},{"date":"2026-03-20","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNZ1o3UzIxdnVhaUlsWTZ4RGMtUGV3eG9ybE9pQXhIVGJWOVl3d3ZGamhCY21qeDlWcGl1WnpyUjJuTzl0ZVpweElPdzBFZFNyT1JZMmpORXJBYkJUTjdmRTg2SjFJTnIxRGZXU05QcFBDMVQtMjU5T2VYcm9tYVhERENFNERUNDJBaThlU2gzbkY1TEt4NlpTa3E5M05xUUJzVUEwMl9LdzU0bVhZVGFMVGs5RGxLaVkxUFZsZDBIa2pyRzlyaHdOaEl2clRMNUxYbkg1NTlWcw?oc=5","date":"2026-03-12","type":"pipeline","source":"proactiveinvestors.com","summary":"Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board - proactiveinvestors.com","headline":"Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQZGFUbW5JMWtoc01tOVJzYnZtZ1NDVVdXS3BUTGpnRnNqUy1wSWtnbU1CZ2tCSFFZd2t1bzQzWU4xcERFdG9tbm1qSUtaelFuemc0MUJicHJUbUphNEtPVjZyTk50c3F6NV9IdUtrTFJlWDhHektEUHNXZnk3eVRMNGdiWFB2SzM1cjlaS1VGbkI3T3VGMGhPTzJmcXMybzVsY25SeWszZkdpNWhjUHpJS0tPTU1RRGlkTEE?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Gene-editing biotech Cellectis sets March 19 release for 2025 results - Stock Titan","headline":"Gene-editing biotech Cellectis sets March 19 release for 2025 results","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNOGFRQzREazZ6TFU0eHk4NGVvZkNzSHNfcFFTYXJ0d3Ztdm5oMG01ams3YXpHYTVBQ19KYlZRVW5jUHlHdVZxVFEzelBZUFJISVBJVktMUzNZS3pYR1RuRktITGRQMWJKYTFncWJrdlFPajBSdGdiWUttYXViNXE0c1VuNGZKUEZldFJ0S2hlSWJoa294SElQSTEwVUtqMDBVNVdSVldEaWl1RnJZMlBZ?oc=5","date":"2026-03-04","type":"pipeline","source":"Stock Titan","summary":"Cellectis lists 100,590,994 shares, 105,825,561 voting rights - Stock Titan","headline":"Cellectis lists 100,590,994 shares, 105,825,561 voting rights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZklZNXBBSi1YalNSSHVTTU9UaEFqZmtjUS1ybUliaG1RUXp0bEQtX1ZuVEN3c0RMY0ZIUlJGR0lzMldWZWZlUGhQTlVRcEgzTGFaQWw5cTFQTmVEQzF2bFVBY3luMU5fa0FuQjNyR2V0WXFZNjFpQ21DTmh5YmxKZ0RKMW1mNHlJcjdoZXBNUWpDcll1T2d0elpoY2NQZDNkeUVJQVY3cjluYnhHN3MyUkM0REJxUkZlQ2hr?oc=5","date":"2026-02-11","type":"trial","source":"Fierce Biotech","summary":"'The only thing that saves us is data': Allogeneic CAR-T biotechs fight for relevance as industry moves on - Fierce Biotech","headline":"'The only thing that saves us is data': Allogeneic CAR-T biotechs fight for relevance as industry moves on","sentiment":"neutral"},{"date":"2026-01-08","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-15","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOczFQaHVsWk96ODh5ZGhsZXM1WmhwZ2RTWTBUZGxpSUVIZS1MNkFqWXY0azNsQWZ0aG0yUS00bTVvTUVMX21QOFRKU3NXMTd3Q1Z0OEFxRHg0Sy11Q2ZMV0VJN0R1dFJMUmtDYzJQZDYzMXY4ZkEtN3hYUEt1a01iaXZPZThqWmowX2ExcHJtYWRpd09UME5RZXQ2d0d3eDBs?oc=5","date":"2025-12-11","type":"deal","source":"Seeking Alpha","summary":"Cellectis’ Allogeneic CAR-T Potential Still Justifies A “Buy” (NASDAQ:CLLS) - Seeking Alpha","headline":"Cellectis’ Allogeneic CAR-T Potential Still Justifies A “Buy” (NASDAQ:CLLS)","sentiment":"neutral"},{"date":"2025-12-08","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-05","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-11-19","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMU41dWl1NXZJRFJ0TUxuWlJ5NHBVbUVFR1g3YWtILUlqek1COXRGT2pkTHNrRGZ6NmdkeUNzTkR5UjN5QXJGWmNqNHNiVXR4RkxUVmJoY1JhZGwyc1Z3dlhWX0RHdHE5cDZLQzFfN3BqMGZSc3NzZUMxVkFsVTlJbXhRTEp3ZG93VUFfejh6X3VMdGROazZxS3d6Ukg4OEZuWHJ4Ni1KaThuX0U?oc=5","date":"2025-11-15","type":"pipeline","source":"富途牛牛","summary":"European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - 富途牛牛","headline":"European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - 富途牛牛","sentiment":"neutral"},{"date":"2025-11-07","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"}],"patents":[{"drugName":"UCART19","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Kite Pharma","Novartis","Gilead Sciences"],"therapeuticFocus":["Immuno-Oncology","Cell and Gene Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":224,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.54,"previousClose":3.36,"fiftyTwoWeekHigh":5.48,"fiftyTwoWeekLow":1.17,"fiftyTwoWeekRange":"1.17 - 5.48","fiftyDayAverage":3.67,"twoHundredDayAverage":3.44,"beta":2.71,"enterpriseValue":124215736,"forwardPE":-5.7,"priceToBook":3.37,"priceToSales":4.47,"enterpriseToRevenue":1.56,"enterpriseToEbitda":-5.71,"pegRatio":0,"ebitda":-21750000,"ebitdaMargin":-27.3,"freeCashflow":-25282376,"operatingCashflow":-39401000,"totalDebt":86691000,"debtToEquity":114.2,"currentRatio":1.62,"returnOnAssets":-5.8,"returnOnEquity":-65.3,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":4,"targetMeanPrice":7.25,"targetHighPrice":10,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0,"institutionHeldPercent":17,"sharesOutstanding":72590994,"floatShares":46679639,"sharesShort":350861,"shortRatio":7.2,"shortPercentOfFloat":0.3,"epsTrailing":-0.67,"epsForward":-0.62,"revenuePerShare":0.79,"bookValue":1.05,"officers":[{"age":60,"name":"Dr. Andre  Choulika Ph.D.","title":"Co-Founder, CEO & Director"},{"age":58,"name":"Dr. David J. Sourdive Ph.D.","title":"Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director"},{"age":36,"name":"Mr. Arthur  Stril","title":"CFO & Chief Business Officer"},{"age":null,"name":"Valerie  Cros","title":"Principal Financial Officer & Principal Accounting Officer"},{"age":null,"name":"Mr. Jean Charles Epinat Ph.D.","title":"Chief Technological Officer"},{"age":62,"name":"Dr. Philippe  Duchateau Ph.D.","title":"Chief Scientific Officer"},{"age":43,"name":"Ms. Marie-Bleuenn  Terrier","title":"General Counsel & Secretary of the Board of Directors"},{"age":null,"name":"Pascalyne  Wilson","title":"Director of Communications"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.cellectis.com","phone":"33 1 81 69 16 00"}}